Drugs / MER3101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03624062 | Aug 2020 → Jun 2025 | type 1 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MER3101 | “MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion.” NCT03624062 ↗ |
| Modality | Vaccine | “3 doses of progressively higher IBC antigen doses of the vaccine” NCT03624062 ↗ |
| Route | Intramuscular | “receive two intramuscular doses at days 0 and 28” NCT03624062 ↗ |